Vaccinex welcomes inquiries from potential scientific collaborators, service clients, and biopharmaceutical development partners. Please contact us at busdev@vaccinex.com or phone (585) 271-2700 for immediate assistance.

Collaboration Partner	Description
Teva Pharmaceuticals	Co-development collaboration in which Teva and Vaccinex will develop and commercialize a novel therapeutic antibody for Multiple Sclerosis (MS) and oncology.
GlaxoSmithKline	Vaccinex and EUSA Pharma licensed Vaccinex's fully human anti-IL6 antibody (Azintrel®) to GSK.
Biocon Limited	Co-development collaboration in which Biocon and Vaccinex jointly discover, develop and commercialize therapeutic antibody products.
Bayer Schering Pharma	Collaboration to identify disease targets and potentially develop novel therapeutic antibodies for the treatment of cancer.

Business Development Contact:

Business Development
Vaccinex Inc.
1895 Mount Hope Ave.
Rochester, NY 14620
Phone: 585-271-2700 ext. 123
Fax: 585-271-2766
E-mail: busdev@vaccinex.com